Patient-reported data on the severity of Von Willebrand disease.

IF 3 2区 医学 Q2 HEMATOLOGY Haemophilia Pub Date : 2024-10-15 DOI:10.1111/hae.15103
Calvin B van Kwawegen, Karin Fijnvandraat, Marieke J H A Kruip, Joke de Meris, Saskia E M Schols, Karina Meijer, Johanna G van der Bom, Marjon H Cnossen, Karin P M van Galen, Ferdows Atiq, Jeroen Eikenboom, Frank W G Leebeek
{"title":"Patient-reported data on the severity of Von Willebrand disease.","authors":"Calvin B van Kwawegen, Karin Fijnvandraat, Marieke J H A Kruip, Joke de Meris, Saskia E M Schols, Karina Meijer, Johanna G van der Bom, Marjon H Cnossen, Karin P M van Galen, Ferdows Atiq, Jeroen Eikenboom, Frank W G Leebeek","doi":"10.1111/hae.15103","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The severity of Von Willebrand disease (VWD) is currently based on laboratory phenotype. However, little is known about the severity of the patient's experience with the disease. The most recent VWD guidelines highlight the need for patient-reported outcomes (PROs) in VWD.</p><p><strong>Aim: </strong>The study aimed to investigate the patient-perspective on VWD severity and to identify key factors that determine the severity of disease experienced by patients.</p><p><strong>Materials and methods: </strong>Patients participated in a nationwide cross-sectional study on VWD in the Netherlands (WiN-study). Patients filled in a questionnaire containing questions on the experienced severity of VWD (4-point scale), bleeding score (BS) and quality of life (QoL).</p><p><strong>Results: </strong>We included 736 patients, median age of 41.0 years (IQR 23.0-55.0) and 59.5% were women. A total of 443 had type 1, 269 type 2 and 24 type 3 VWD. Self-reported severity of VWD was categorized as severe (n = 52), moderate (n = 171), mild (n = 393) or negligible (n = 120). Classification by historically lowest FVIII:C levels < 0.20 IU/mL as a proxy for severe VWD aligned with patient-reported severity classification with a 72% accuracy. Type 3 VWD (OR = 4.02, 95%CI: 1.72-9.45), higher BS (OR = 1.09, 95%CI: 1.06-1.11), female sex (OR = 1.36, 95%CI: 1.01-1.83), haemostatic treatment in the year preceding study inclusion (OR = 1.53, 95%CI: 1.10-2.13) and historically lowest VWF:Act levels (OR = 0.26, 95%CI: 0.07-1.00) were independent determinants of patient-reported severity.</p><p><strong>Conclusion: </strong>This study shows that patient-reported data provide novel insights into the determinants of experienced disease severity. Our findings highlight the need for studies on PROs with validated questionnaires to assess the burden of VWD.</p>","PeriodicalId":12819,"journal":{"name":"Haemophilia","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haemophilia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/hae.15103","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The severity of Von Willebrand disease (VWD) is currently based on laboratory phenotype. However, little is known about the severity of the patient's experience with the disease. The most recent VWD guidelines highlight the need for patient-reported outcomes (PROs) in VWD.

Aim: The study aimed to investigate the patient-perspective on VWD severity and to identify key factors that determine the severity of disease experienced by patients.

Materials and methods: Patients participated in a nationwide cross-sectional study on VWD in the Netherlands (WiN-study). Patients filled in a questionnaire containing questions on the experienced severity of VWD (4-point scale), bleeding score (BS) and quality of life (QoL).

Results: We included 736 patients, median age of 41.0 years (IQR 23.0-55.0) and 59.5% were women. A total of 443 had type 1, 269 type 2 and 24 type 3 VWD. Self-reported severity of VWD was categorized as severe (n = 52), moderate (n = 171), mild (n = 393) or negligible (n = 120). Classification by historically lowest FVIII:C levels < 0.20 IU/mL as a proxy for severe VWD aligned with patient-reported severity classification with a 72% accuracy. Type 3 VWD (OR = 4.02, 95%CI: 1.72-9.45), higher BS (OR = 1.09, 95%CI: 1.06-1.11), female sex (OR = 1.36, 95%CI: 1.01-1.83), haemostatic treatment in the year preceding study inclusion (OR = 1.53, 95%CI: 1.10-2.13) and historically lowest VWF:Act levels (OR = 0.26, 95%CI: 0.07-1.00) were independent determinants of patient-reported severity.

Conclusion: This study shows that patient-reported data provide novel insights into the determinants of experienced disease severity. Our findings highlight the need for studies on PROs with validated questionnaires to assess the burden of VWD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
关于 Von Willebrand 病严重程度的患者报告数据。
导言:目前,Von Willebrand 病(VWD)的严重程度是根据实验室表型确定的。然而,人们对患者的病情严重程度知之甚少。最新的 VWD 指南强调了 VWD 患者报告结果(PROs)的必要性。目的:该研究旨在调查患者对 VWD 严重程度的看法,并确定决定患者疾病严重程度的关键因素:患者参与了荷兰一项全国性的 VWD 横断面研究(WiN-研究)。患者填写了一份调查问卷,其中包含关于VWD严重程度(4分制)、出血评分(BS)和生活质量(QoL)的问题:我们共纳入了 736 名患者,中位年龄为 41.0 岁(IQR 23.0-55.0),59.5% 为女性。共有 443 名 1 型、269 名 2 型和 24 名 3 型 VWD 患者。自我报告的 VWD 严重程度分为重度(52 人)、中度(171 人)、轻度(393 人)或可忽略不计(120 人)。按历史最低 FVIII:C 水平分类 结论:这项研究表明,患者报告的数据为了解疾病严重程度的决定因素提供了新的视角。我们的研究结果突出表明,有必要使用经过验证的问卷对患者的PROs进行研究,以评估VWD的负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Haemophilia
Haemophilia 医学-血液学
CiteScore
6.50
自引率
28.20%
发文量
226
审稿时长
3-6 weeks
期刊介绍: Haemophilia is an international journal dedicated to the exchange of information regarding the comprehensive care of haemophilia. The Journal contains review articles, original scientific papers and case reports related to haemophilia care, with frequent supplements. Subjects covered include: clotting factor deficiencies, both inherited and acquired: haemophilia A, B, von Willebrand''s disease, deficiencies of factor V, VII, X and XI replacement therapy for clotting factor deficiencies component therapy in the developing world transfusion transmitted disease haemophilia care and paediatrics, orthopaedics, gynaecology and obstetrics nursing laboratory diagnosis carrier detection psycho-social concerns economic issues audit inherited platelet disorders.
期刊最新文献
The haemophilia joint health score for the assessment of joint health in patients with haemophilia. Performance of instrumental activities of daily living in patients with haemophilic arthropathy. A cross-sectional cohort study. A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results. Breaking barriers in haemophilia A care: One-year real-world experience with emicizumab prophylaxis at Civil Service Hospital, Kathmandu, Nepal. Moderate haemophilia A: Recommendations from a Spanish panel of experts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1